Menu
  • Find a Doctor
  • International Patients
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • News & Stories
  • Transfer a Patient
  • NN108 TopCSPN

    The TopCSPN study is a multicenter, randomized, parallel-group, double-blind, placebo-controlled, Phase II clinical trial. The purpose of this study is to determine if a target daily dose of 100 milligrams of oral topiramate slows the progression of neuropathy and improves quality of life for adults age 18-80 with cryptogenic sensory peripheral neuropathy (commonly called idiopathic neuropathy), who also have symptoms of metabolic disease (such as high cholesterol, elevated blood sugar, high blood pressure, and abdominal obesity) at screening.

    A variety of assessments and questionnaires will be performed during study visits to evaluate if topiramate improves neuropathy symptoms. These study visits will be conducted over a 96-week (24-month) treatment period, with in-person visits occurring every 16 weeks and monthly follow-up phone calls in between visits.

    Principal Investigator: Erik Ortega, MD

    Enrollment Contact
    Nicole Turcotte
    (602) 406-4775
    [email protected]

    About Barrow Neurological Institute

    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premier destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.